LEO Pharma Acquires Dersimelagon for Up to $435 Million
LEO Pharma agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma for up to $435 million in upfront and near-term milestone payments, plus additional downstream milestones and tiered royalties. Dersimelagon is an oral…
